R&D Systems™ Recombinant Human LILRA4/CD85g/ILT7 Protein

Description

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.

The Recombinant Human LILRA4/CD85g/ILT7 Protein is derived from NS0. The Recombinant Human LILRA4/CD85g/ILT7 Protein has been validated for the following applications: Bioactivity.

Specifications

• Accession Number: P59901
• For Use With (Application): Bioactivity
• Gene ID (Entrez): 23547
• Molecular Weight (g/mol): Observed M.W.: 60-73kDa, reducing conditions, Theoretical M.W.: 47kDa
• Quantity: 50 μg
• Source: Mouse myeloma cell line,NS0-derived human LILRA4/CD85g/ILT7 protein Glu24-Asn446,with a C-terminal 6-His tag
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
• Endotoxin Concentration: <0.10 EU per 1μg of the protein by the LAL method.
• Gene Alias: CD85 antigen-like family member G, CD85g, CD85g antigen, ILT7, ILT-7, ILT7MGC129598, Immunoglobulin-like transcript 7, leukocyte immunoglobulin-like receptor subfamily A member 4, leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 4, leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member4, MGC129597
• Common Name: ILT7/CD85g/LILRA4
• Gene Symbol: LILRA4
• Biological Activity: Measured by its binding ability in a functional ELISA. When Recombinant Human LILRA4/CD85g/ILT7 is coated at 1μg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 binds with a typical ED50 = 20-120ng/mL.
• Conjugate: Unconjugated
• Species: Human
• Recombinant: Recombinant
• Expression System: Mouse myeloma cell line, NS0-derived Glu24-Asn446, with a C-terminal 6-His tag
• Purity or Quality Grade: >90%, by SDS-PAGE with Silver Staining